Archived explainer. For the current picture see today's ERAS page.
ERASCA INC (ERAS) is up +7.43% in the latest session. Our newswire has captured 13 stories on ERAS across 8 sources in the last 36 hours, with AI sentiment reading bearish (avg 38/100).
ERAS stock is up 7.43% at $19.23 as of the latest trade, driven by a combination of positive clinical data and a large public offering. The company announced updated preliminary data for its ERAS-0015 drug in solid tumors and priced an upsized $550 million offering of common stock. These developments have sparked investor interest despite the stock opening with a small gap down.
The most recent news from Erasca includes the announcement of updated Phase 1 data for ERAS-0015, reported by Seeking Alpha on July 13. The data highlights the drug’s potential in treating RAS-driven cancers, with pivotal trials in lung and pancreatic cancer expected in 2027. This update was followed by the pricing of a $550 million public offering, as reported by MarketChameleon and Seeking Alpha. The offering includes 31.43 million shares priced at $17.50 per share, with underwriters granted an option to purchase an additional $75 million in shares. The offering is intended to fund R&D and corporate initiatives, according to multiple reports.
The stock opened at $17.70, slightly below the prior close of $17.90, but quickly rallied to a session high of $19.54 within the first hour of trading. The intraday volume of 1.9 million shares is significantly below the 3-month average. The stock has traded within a 52-week range of $1.33 to $24.28, and currently has a market cap of $5.8 billion. Erasca remains unprofitable, with a trailing twelve-month EPS of -0.96. The AI sentiment for the coverage over the past 36 hours is 38/100, slightly below neutral. Retail traders on X have expressed mixed sentiment, with recent chatter scoring 24/100.
The stock is expected to close the offering on July 15, subject to customary conditions. Investors should monitor the execution of the offering and the impact of the raised capital on R&D progress. Additionally, the upcoming pivotal trials for ERAS-0015 in 2027 will be a key focus for coverage and sentiment in the coming months.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Philadelphia, Pennsylvania--(Newsfile Corp. - July 14, 2026) - National plaintiffs' law firm Berger...
Erasca announces the pricing of a $550 million upsized public offering, allocating proceeds towards R&D and corporate initiatives. The expanded share offering, led by major underwriters, highlights the company’s commitment to precision oncology and positions Erasca for future growth.
Erasca (ERAS) announced the pricing of an upsized public offering of 31.43M shares of its common stock at a public offering price of $17.50 per share. The offering was upsized from an initially proposed target of $500M. All shares are being sold by the
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers,...
31.4M shares are priced at $17.50; closing is expected July 15, subject to customary conditions, with proceeds intended for R&D and working capital.
An update from Erasca ( ($ERAS) ) is now available. On July 13, 2026, Erasca reported updated preliminary Phase 1 data from its AURORAS-1 trial of ERAS-0015 in RAS-...
Erasca (ERAS) plans a $500M public stock offering plus a $75M option to fund R&D and working capital.
Filed: 2026-07-13 AccNo: 0001193125-26-302045 Size: 174 KB Item 8.01: Other Events
More on ERAS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ERAS move explainers: 2026-07-16 · 2026-07-14